Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
dMMR/MSI-H colorectal cancer patients are the dominant population of immunotherapy/neoadjuvant immunotherapy, but imaging evaluation of immunotherapy efficacy is insufficient. There are some cases, although no disease remission was found on imaging,pathological complete response (pCR) was confirmed after surgery. Meanwhile,previous studies have shown that dynamic changes in ctDNA can help assess immunotherapy efficacy. Therefore, we propose to conduct a multicenter, prospective, observational clinical study to explore the efficacy prediction and monitoring value of ctDNA in immunotherapy for advanced or locally advanced dMMR/MSI-H colorectal cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z zaawansowanym rakiem jelita grubego.
- •Pacjenci, którzy otrzymują lub będą otrzymywać immunoterapię.
- •Pacjenci w dobrym ogólnym stanie zdrowia, którzy mogą przeżyć co najmniej 12 tygodni.
✗ Disqualifies
- •Obecność innych, nieuleczonych chorób nowotworowych.
- •Poważne choroby współistniejące, które mogą utrudnić udział w badaniu.
- •Choroby autoimmunologiczne (organizmu atakującego własne tkanki), które dyskwalifikują z niektórych terapii.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- June 30, 2026
- Sex
- No restrictions
Locations (2)
Peking Union Medical College Hospital
Beijing, China
Fudan University Shanghai Cancer Center
Shanghai, China
Trial contact
Xiaoyan Zhou, PhD
Junjie Peng, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.